Associations - EGFR L861Q

EGFR L861Q EGFR L861Q	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: B - Late Trials
EGFR L861Q EGFR L861Q	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: B - Late Trials
EGFR L861Q EGFR L861Q	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR inhibitor Sensitive: B - Late Trials
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C2 – Inclusion Criteria
EGFR L861Q EGFR L861Q	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C2 – Inclusion Criteria
EGFR L861Q EGFR L861Q	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C2 – Inclusion Criteria
EGFR L861Q EGFR L861Q	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: C2 – Inclusion Criteria
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials
EGFR L861Q EGFR L861Q	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: C3 – Early Trials
EGFR L861Q EGFR L861Q	Lung Cancer Lung Cancer	pan-ErbB inhibitor Sensitive: D – Preclinical
EGFR L861Q EGFR L861Q	Esophageal Cancer Esophageal Cancer	erlotinib Resistant: D – Preclinical
EGFR L861Q EGFR L861Q	Esophageal Cancer Esophageal Cancer	cetuximab Resistant: D – Preclinical
EGFR L861Q EGFR L861Q	Esophageal Cancer Esophageal Cancer	afatinib Sensitive: D – Preclinical